A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced the appointment of Paul Marshall as senior vice president of technical operations and Brian Drazba as vice president of finance and chief financial officer. Mr. Marshall will be responsible for A.P. Pharma’s manufacturing operations, including for APF530, the Company’s lead product candidate for the prevention of chemotherapy-induced nausea and vomiting. He has served as a consultant to A.P. Pharma for the last three months since leaving Amylin Pharmaceuticals, where he was Senior Vice President Operations in charge of global manufacturing prior to that company being sold to Bristol-Myers Squibb in 2012. Mr. Drazba will lead the financial operations and fiduciary reporting responsibilities for the Company. He comes to A.P. Pharma from ISTA Pharmaceuticals where he was vice president finance and chief accounting officer helping to grow that company into the third largest branded prescription eye care business in the United States.
“As A.P. Pharma approaches the resubmission of its new drug application for APF530, we are committed to having the right expertise in place to guide the organization through 2014 and beyond,” said Barry D. Quart, Pharm.D., A.P. Pharma’s Chief Executive Officer. “Both Paul and Brian have proven experience in their given disciplines and we believe they will have a rapid, positive impact on the organization’s development. We welcome them to our team and look forward to their value-add perspectives.”
Mr. Marshall has 27 years of experience in the development and commercialization of pharmaceutical products, including manufacturing and supply chain responsibility for 14 approved drugs and biologics, 3 of which achieved blockbuster (sales >$1B) status. Since 2006, Mr. Marshall has held ascending executive positions within Amylin Pharmaceuticals, Inc., including Senior Vice President, Operations. Prior to his work at Amylin, Mr. Marshall held executive manufacturing positions at Amgen, Inc. and Baxter International. He has held management positions at Creative BioMolecules, Welgen Manufacturing Partnership (now Amgen, Rhode Island), Repligen Corporation and Damon Biotech. Mr. Marshall received a Bachelor of Science and a Master of Science in Biology from the University of Massachusetts at Dartmouth and completed three years of post-graduate work concentrating in hematology and coagulation research at Brown University.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts